## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims

Claims 1-16 (Cancelled)

Claim 17 (new): A pharmaceutical dosage unit for oral, transmucosal or transdermal administration containing at least 10 $\mu$g of an androgenic steroid selected from the group consisting of 15-hydroxytestosterones, 16-hydroxytestosterones, precursors thereof, mixtures of these hydroxytestosterones, and precursors of these mixtures of these hydroxytestosterones; and a pharmaceutically acceptable excipient.

Claim 18 (new): The pharmaceutical dosage unit according to claim 17, wherein the steroid is selected from the group consisting of 15$\alpha$-hydroxytestosterone, 15$\beta$-hydroxytestosterone, 16$\beta$-hydroxytestosterone, precursors thereof, mixtures of these hydroxytestosterones, and precursors of these mixtures of these hydroxytestosterones.

Claim 19 (new): The pharmaceutical dosage unit according to claim 18, wherein the steroid is selected from the group consisting of 15$\alpha$-hydroxytestosterone, 15$\beta$-hydroxytestosterone, precursors, mixtures of these hydroxytestosterones, and precursors of these mixtures of these hydroxytestosterones.

Claim 20 (new): The pharmaceutical dosage unit according to claim 19, wherein the steroid is selected from the group consisting of 15$\alpha$-hydroxytestosterone, precursors thereof, mixtures of 15$\alpha$-hydroxytestosterone, and precursors of these mixtures of these hydroxytestosterones.

Claim 21 (new): The pharmaceutical dosage unit according to claim 19, wherein the steroid is selected from the group consisting of 15$\beta$-hydroxytestosterone, precursors thereof, mixtures of 15$\beta$-hydroxytestosterone, and precursors of these mixtures of these hydroxytestosterones.

Claim 22 (new): The pharmaceutical dosage unit according to claim 18, wherein the steroid is selected from the group consisting of 16$\beta$-hydroxytestosterone, precursors thereof, mixtures of 16$\beta$-hydroxytestosterone, and precursors of these mixtures of these hydroxytestosterones.

Claim 23 (new): The pharmaceutical dosage unit according to claim 17, wherein the precursors of the hydroxytestoserones are derivatives of the hydroxytestosterones wherein the hydrogen atom of at least one hydroxylgroup has been substituted by an acyl radical of a hydrocarbon carboxylic, sulfonic or sulfamic acid of 1-25 carbon atoms; tetrahydrofuranyl; tetrahydropyranal; or a straight or branched chain glycosydic residue containing 1-20 glycosidic units per residue.

Claim 24 (new): The pharmaceutical dosage unit according to claim 17, wherein the dosage unit is an oral dosage unit.

Claim 25 (new): The pharmaceutical dosage unit according to claim 24, wherein the dosage unit is a tablet, a capsule, a cachet, a pellet, a pill, a powder or granules.

Claim 26 (new): The pharmaceutical dosage unit according to claim 17, wherein the dosage unit contains between 20 $\mu$g and 1000 mg of the androgenic steroid.

Claim 27 (new): The pharmaceutical dosage unit according to claim 17, wherein the dosage unit additionally contains at least 10 $\mu$g of a progestogen and/or at least 10 $\mu$g of an estrogen.

Claim 28 (new): A method of curatively or prophylactically treating a mammal, said method comprising oral, transmucosal or transdermal administration to said mammal of a dosage unit according to claim 17.

Claim 29 (new): The method according to claim 28, wherein the method comprises oral administration of the dosage unit to said mammal.

Claim 30 (new): The method according to claim 28, wherein the method comprises the administration of the steroid in an average daily amount in the range of 0.5 $\mu$g to 1.5 mg per kg of bodyweight.

Claim 31 (new): The method according to claim 28 for use as at least one of the following: a method of treating or preventing androgen deficiency; a method of hormonal contraception; a method of treating or preventing wasting syndrome, anti-retroviral drug induced lipodystrophia, lack of well-being or fatigue in HIV infected individuals; a method of reversing catabolic state caused by a chronic illness, surgical intervention, oncological condition, trauma and/or malnutrition; a method of treating or preventing leydig cell dysfunction and germinal epithelial damage following cytotoxic chemotherapy; a method of treating or preventing fatigue or maintaining weight, hemoglobin or neutrophil count during or subsequent to cytotoxic chemotherapy or radiotherapy; a method of treating or preventing benign gynaecological disorders; a method of improving libido; a method of treating or preventing delayed puberty; or a method of supporting female-to-male conversion.